Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496423 | 0.82 | KMT2A (0.41) | HCAR3LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1656833 | 0.81 | KMT2A (0.43) | LMNASMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL30515532 | 0.78 | ALDH1A1 (0.41) | LMNASMN1; SMN2ALDH1A1MAPTTDP1 | |
| SCHEMBL6217472 | 0.78 | ALDH1A1 (0.41) | LMNASMN1; SMN2ALDH1A1MAPTTDP1 | |
| SCHEMBL1656823 | 0.76 | HCAR3 (0.42) | HCAR3GAAMEN1KMT2A | |
| SCHEMBL25329286 | 0.74 | TDP1 (0.61) | LMNASMN1; SMN2ALDH1A1MAPTTDP1 | |
| SCHEMBL4085561 | 0.74 | LMNA (0.41) | HCAR3LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL8161303 | 0.73 | GPR35 (0.42) | LMNASMN1; SMN2ALDH1A1TDP1L3MBTL1 | |
| SCHEMBL22325943 | 0.73 | LMNA (0.40) | HCAR3LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL15774437 | 0.72 | HCAR3 (0.49) | HCAR3LMNASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | HCAR3 3963/4885LMNA 1625/4885SMN1; SMN2 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.